PI3 kinase is an enzyme that is overproduced by some cancers and can fuel cancer growth. PI3 kinase activity is known to be elevated in many hematologic cancers. IPI-145 is an investigational drug designed to inhibit cancer growth by blocking PI3 kinase activity.
In this study, researchers are determining the highest dose of IPI-145 that can be given safely in patients with advanced lymphoma, leukemia, or multiple myeloma that persists or has worsened despite standard therapy. IPI-145 is a capsule that is taken orally (by mouth).